Annual revenue of Jiangsu Hengrui Pharmaceuticals 2015-2022
In 2022, the Chinese firm Jiangsu Hengrui Pharmaceuticals generated a total revenue of 21.28 billion yuan, indicating a slight drop after the steady growth over the past few years. The core products of Jiangsu Hengrui Medicine include anti-tumor medicines, pain-killers, and anti-infection medicines.